IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
1.580
0.00 (0.00%)
At close: Aug 29, 2025, 4:00 PM
1.590
+0.010 (0.63%)
After-hours: Aug 29, 2025, 6:38 PM EDT
IO Biotech Employees
IO Biotech had 80 employees as of December 31, 2024. The number of employees increased by 12 or 17.65% compared to the previous year.
Employees
80
Change (1Y)
12
Growth (1Y)
17.65%
Revenue / Employee
n/a
Profits / Employee
-$1,299,825
Market Cap
104.09M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 80 | 12 | 17.65% |
| Dec 31, 2023 | 68 | 11 | 19.30% |
| Dec 31, 2022 | 57 | 25 | 78.13% |
| Dec 31, 2021 | 32 | 21 | 190.91% |
| Dec 31, 2020 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IOBT News
- 15 days ago - IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights - GlobeNewsWire
- 17 days ago - IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma - Seeking Alpha
- 18 days ago - IO Biotech's cancer vaccine shows improvement in late-stage study goal - Reuters
- 18 days ago - IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed - GlobeNewsWire
- 19 days ago - IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma - GlobeNewsWire
- 3 months ago - IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference - GlobeNewsWire
- 3 months ago - IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewsWire
- 4 months ago - IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 - GlobeNewsWire